We’re excited to announce that Ossium will be exhibiting at the 2025 Transplantation & Cellular Therapy (Tandem) Meetings of ASTCT and CIBMTR, taking place from February 12-15 in Honolulu, Hawaii. This premier event brings together experts and professionals in the field of transplantation and cellular therapy to discuss the latest advancements, research, and innovations shaping the future of patient care.

Ossium is dedicated to revolutionizing the field of cell therapy and transplantation with our proprietary bone marrow banking platform. We are thrilled to engage with the global transplant community at Tandem 2025 and share how our innovative graft source is improving the access, speed, and quality of transplants for patients.

Visit us at Booth 629 to connect with our team and learn more about the company’s latest developments, including:

• PRESERVE I Clinical Trial: This ongoing trial is actively recruiting patients and aims to evaluate allogeneic HCT with Ossium’s organ donor bone marrow for patients with hematologic malignancies.
• HOPE Program: Ossium’s expanded access program is available for patients in need of an allogeneic HCT that are unable to enroll in PRESERVE I.

For more details, read our full press release here.

We look forward to seeing you in Honolulu!